Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | STK11 |
| Variant | F298L |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | STK11 F298L lies within the protein kinase domain of the Stk11 protein (UniProt.org). F298L has been identified in the scientific literature (PMID: 27615706), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Oct 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
STK11 mutant STK11 F298L |
| Transcript | NM_000455.5 |
| gDNA | chr19:g.1221978T>C |
| cDNA | c.892T>C |
| Protein | p.F298L |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001407255.1 | chr19:g.1221978T>C | c.892T>C | p.F298L | RefSeq | GRCh38/hg38 |
| XM_005259618 | chr19:g.1221978T>C | c.892T>C | p.F298L | RefSeq | GRCh38/hg38 |
| NM_000455.5 | chr19:g.1221978T>C | c.892T>C | p.F298L | RefSeq | GRCh38/hg38 |
| NM_000455.4 | chr19:g.1221978T>C | c.892T>C | p.F298L | RefSeq | GRCh38/hg38 |
| NM_000455 | chr19:g.1221978T>C | c.892T>C | p.F298L | RefSeq | GRCh38/hg38 |
| XM_005259618.3 | chr19:g.1221978T>C | c.892T>C | p.F298L | RefSeq | GRCh38/hg38 |
| XM_005259617.3 | chr19:g.1221978T>C | c.892T>C | p.F298L | RefSeq | GRCh38/hg38 |
| XM_005259617 | chr19:g.1221978T>C | c.892T>C | p.F298L | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| STK11 F298L | pituitary carcinoma | predicted - sensitive | Everolimus + Radiotherapy | Case Reports/Case Series | Actionable | In a clinical case study, a patient with adenocorticotropic pituitary carcinoma harboring STK11 F298L demonstrated stable disease and clinical benefit for greater than 6 months following treatment with Afinitor (everolimus), along with radiotherapy (PMID: 27615706). | 27615706 |